| Year |
Citation |
Score |
| 2022 |
McCunn P, Chen X, Gimi B, Green AI, Khokhar JY. Glutamine and GABA alterations in cingulate cortex may underlie alcohol drinking in a rat model of co-occurring alcohol use disorder and schizophrenia: an 1H-MRS study. Schizophrenia (Heidelberg, Germany). 8: 67. PMID 35999232 DOI: 10.1038/s41537-022-00272-6 |
0.691 |
|
| 2020 |
Brunette MF, Correll CU, O'Malley SS, McDonnell D, DiPetrillo L, Jiang Y, Simmons A, Silverman BL, Citrome L, Green AI. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial. The Journal of Clinical Psychiatry. 81. PMID 32160422 DOI: 10.4088/Jcp.19M12786 |
0.482 |
|
| 2019 |
Archibald L, Brunette MF, Wallin DJ, Green AI. Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder. Alcohol Research : Current Reviews. 40. PMID 31886105 DOI: 10.35946/arcr.v40.1.06 |
0.352 |
|
| 2019 |
Henricks AM, Sullivan EDK, Dwiel LL, Keus KM, Adner ED, Green AI, Doucette WT. Sex differences in the ability of corticostriatal oscillations to predict rodent alcohol consumption. Biology of Sex Differences. 10: 61. PMID 31849345 DOI: 10.1186/S13293-019-0276-0 |
0.72 |
|
| 2019 |
Henricks AM, Dwiel LL, Deveau NH, Simon AA, Ruiz-Jaquez MJ, Green AI, Doucette WT. Corticostriatal Oscillations Predict High vs. Low Drinkers in a Rat Model of Limited Access Alcohol Consumption. Frontiers in Systems Neuroscience. 13: 35. PMID 31456669 DOI: 10.3389/Fnsys.2019.00035 |
0.731 |
|
| 2019 |
Dwiel LL, Khokhar JY, Connerney MA, Green AI, Doucette WT. Finding the balance between model complexity and performance: Using ventral striatal oscillations to classify feeding behavior in rats. Plos Computational Biology. 15: e1006838. PMID 31009448 DOI: 10.1371/Journal.Pcbi.1006838 |
0.748 |
|
| 2019 |
Whitton AE, Green AI, Pizzagalli DA, Roth RM, Williams JM, Brunette MF. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. Schizophrenia Bulletin. PMID 30690638 DOI: 10.1093/Schbul/Sby185 |
0.321 |
|
| 2019 |
Green A, Khokhar J. 36. SCHIZOPHRENIA AND SUBSTANCE USE DISORDER: A UNIFYING HYPOTHESIS Schizophrenia Bulletin. 45: S147-S147. DOI: 10.1093/Schbul/Sbz022.147 |
0.705 |
|
| 2018 |
Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, et al. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety. Alcoholism, Clinical and Experimental Research. PMID 30403402 DOI: 10.1111/Acer.13917 |
0.373 |
|
| 2018 |
Doucette WT, Dwiel L, Boyce JE, Simon AA, Khokhar JY, Green AI. Machine Learning Based Classification of Deep Brain Stimulation Outcomes in a Rat Model of Binge Eating Using Ventral Striatal Oscillations. Frontiers in Psychiatry. 9: 336. PMID 30123143 DOI: 10.3389/Fpsyt.2018.00336 |
0.758 |
|
| 2018 |
Khokhar JY, Henricks AM, Sullivan EDK, Green AI. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in Pharmacology (San Diego, Calif.). 82: 137-162. PMID 29413518 DOI: 10.1016/Bs.Apha.2017.09.009 |
0.72 |
|
| 2018 |
Burke E, Wojcik J, Seidman LJ, Green A, Woo TW. F43. POTENTIATION OF INHIBITORY NEUROTRANSMISSION IN THE TREATMENT OF RECENT-ONSET SCHIZOPHRENIA BY MODIFICATION OF DEVELOPMENTAL PRUNING OF PREFRONTAL CIRCUITRY Schizophrenia Bulletin. 44: S235-S236. DOI: 10.1093/Schbul/Sby017.574 |
0.385 |
|
| 2018 |
Whitton A, Green A, Pizzagalli D, Williams J, Brunette M. S244. Potent Dopamine D2 Receptor Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia Biological Psychiatry. 83: S443. DOI: 10.1016/J.Biopsych.2018.02.1136 |
0.34 |
|
| 2017 |
Green AI, Khokhar JY. Addiction and schizophrenia: A translational perspective. Schizophrenia Research. PMID 29046253 DOI: 10.1016/J.Schres.2017.10.008 |
0.694 |
|
| 2017 |
Whitfield-Gabrieli S, Fischer AS, Henricks AM, Khokhar JY, Roth RM, Brunette MF, Green AI. Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. Schizophrenia Research. PMID 28823723 DOI: 10.1016/J.Schres.2017.07.029 |
0.777 |
|
| 2017 |
Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research. PMID 28416205 DOI: 10.1016/J.Schres.2017.04.016 |
0.798 |
|
| 2016 |
Brunette MF, Akerman SC, Dawson R, O'Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol (Fayetteville, N.Y.). PMID 27256763 DOI: 10.1016/J.Alcohol.2016.02.006 |
0.416 |
|
| 2016 |
Khokhar JY, Green AI. Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology. 105: 25-34. PMID 26796639 DOI: 10.1016/J.Neuropharm.2016.01.017 |
0.713 |
|
| 2015 |
Doucette WT, Khokhar JY, Green AI. Nucleus accumbens deep brain stimulation in a rat model of binge eating. Translational Psychiatry. 5: e695. PMID 26670280 DOI: 10.1038/Tp.2015.197 |
0.756 |
|
| 2015 |
Chau DT, Khokhar JY, Gulick D, Dawson R, Green AI. Desipramine enhances the ability of paliperidone to decrease alcohol drinking. Journal of Psychiatric Research. 69: 9-18. PMID 26343589 DOI: 10.1016/J.Jpsychires.2015.07.010 |
0.773 |
|
| 2015 |
Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy DL, O'Keefe C, Sommi RW, Steinbook RM, Weeks M. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. The Journal of Clinical Psychiatry. PMID 26302441 DOI: 10.4088/Jcp.13M08838 |
0.491 |
|
| 2015 |
Khokhar JY, Chau DT, Dawson R, Green AI. Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug and Alcohol Dependence. 152: 277-81. PMID 25979645 DOI: 10.1016/J.Drugalcdep.2015.04.003 |
0.73 |
|
| 2015 |
Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Response to "cortico-accumbens circuitry in schizophrenia: merely a reward system?" by Rolland and Jardri (SCHRES-14-D-00731). Schizophrenia Research. 161: 519. PMID 25465412 DOI: 10.1016/J.Schres.2014.10.008 |
0.708 |
|
| 2015 |
Green AI, Khokhar JY. Deconstructing clozapine further: Toward medication for alcohol use disorder in schizophrenia Drug and Alcohol Dependence. 146: e128. DOI: 10.1016/J.Drugalcdep.2014.09.267 |
0.725 |
|
| 2014 |
Akerman SC, Brunette MF, Noordsy DL, Green AI. Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Current Addiction Reports. 1: 251-260. PMID 27226947 DOI: 10.1007/S40429-014-0034-7 |
0.459 |
|
| 2014 |
Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophrenia Research. 158: 176-82. PMID 25037524 DOI: 10.1016/J.Schres.2014.04.033 |
0.737 |
|
| 2014 |
Gulick D, Chau DT, Khokhar JY, Dawson R, Green AI. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry Research. 218: 329-34. PMID 24836200 DOI: 10.1016/J.Psychres.2014.04.038 |
0.772 |
|
| 2014 |
Mesholam-Gately RI, Gibson LE, Seidman LJ, Green AI. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophrenia Research. 155: 45-51. PMID 24685823 DOI: 10.1016/J.Schres.2014.03.002 |
0.459 |
|
| 2013 |
Chau DT, Khokhar JY, Dawson R, Ahmed J, Xie H, Green AI. The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. Alcohol (Fayetteville, N.Y.). 47: 611-8. PMID 24280363 DOI: 10.1016/J.Alcohol.2013.10.002 |
0.7 |
|
| 2013 |
Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine. 7: 277-86. PMID 23728065 DOI: 10.1097/Adm.0B013E31829623F4 |
0.392 |
|
| 2013 |
Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? The Journal of Clinical Psychiatry. 74: e08. PMID 23656852 DOI: 10.4088/Jcp.12012Tx2C |
0.406 |
|
| 2013 |
Gamsby JJ, Templeton EL, Bonvini LA, Wang W, Loros JJ, Dunlap JC, Green AI, Gulick D. The circadian Per1 and Per2 genes influence alcohol intake, reinforcement, and blood alcohol levels. Behavioural Brain Research. 249: 15-21. PMID 23608482 DOI: 10.1016/J.Bbr.2013.04.016 |
0.564 |
|
| 2012 |
Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. The Journal of Clinical Psychiatry. 73: 1463-8. PMID 23218162 DOI: 10.4088/Jcp.12012Co1C |
0.403 |
|
| 2012 |
Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 1421-30. PMID 22324516 DOI: 10.1111/J.1530-0277.2011.01716.X |
0.398 |
|
| 2012 |
Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 406-16. PMID 21950727 DOI: 10.1111/J.1530-0277.2011.01649.X |
0.404 |
|
| 2012 |
Green AI. Long-acting injectable antipsychotic medications in patients with comorbid schizophrenia and substance use disorders Journal of Dual Diagnosis. 8: 62-63. DOI: 10.1080/15504263.2012.647506 |
0.434 |
|
| 2011 |
Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of Dual Diagnosis. 7: 50-63. PMID 25914610 DOI: 10.1080/15504263.2011.570118 |
0.45 |
|
| 2011 |
Chau DT, Ahmed J, Wang TT, Xie H, Dawson R, Green AI. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology. 61: 646-52. PMID 21619888 DOI: 10.1016/J.Neuropharm.2011.05.007 |
0.463 |
|
| 2010 |
Gulick D, Green AI. Role of caloric homeostasis and reward in alcohol intake in Syrian golden hamsters. Physiology & Behavior. 101: 518-26. PMID 20688091 DOI: 10.1016/J.Physbeh.2010.07.019 |
0.629 |
|
| 2010 |
Henderson MB, Green AI, Bradford PS, Chau DT, Roberts DW, Leiter JC. Deep brain stimulation of the nucleus accumbens reduces alcohol intake in alcohol-preferring rats. Neurosurgical Focus. 29: E12. PMID 20672914 DOI: 10.3171/2010.4.Focus10105 |
0.407 |
|
| 2010 |
Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology. 58: 351-6. PMID 19895824 DOI: 10.1016/J.Neuropharm.2009.10.006 |
0.665 |
|
| 2010 |
Noordsy D, Jessica, Green A. Clozapine Vs. Risperidone For People With First Episode Schizophrenia And Co-Occurring Cannabis Use Disorder Schizophrenia Research. 117: 165-166. DOI: 10.1016/J.Schres.2010.02.184 |
0.441 |
|
| 2009 |
Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. The Journal of Clinical Psychiatry. 70: 4-46. PMID 19292973 DOI: 10.4088/JCP.8157su1c.01 |
0.476 |
|
| 2009 |
Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Seidman LJ. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 106: 1279-84. PMID 19164577 DOI: 10.1073/Pnas.0809141106 |
0.349 |
|
| 2009 |
Brunette MF, Dawson R, O'Keefe C, Buckley P, Green AI. An open label study of quetiapine in patients with schizophrenia and alcohol disorders Mental Health and Substance Use: Dual Diagnosis. 2: 203-211. DOI: 10.1080/17523280903156073 |
0.414 |
|
| 2008 |
Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Substance Abuse. 29: 51-63. PMID 19042206 DOI: 10.1080/08897070802218794 |
0.36 |
|
| 2008 |
Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, Abelmann WH, Green AI, Zeind J, Morgan JP. Clozapine-induced myocarditis: role of catecholamines in a murine model. European Journal of Pharmacology. 592: 123-7. PMID 18627770 DOI: 10.1016/J.Ejphar.2008.06.088 |
0.328 |
|
| 2008 |
Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 34: 61-71. PMID 17574793 DOI: 10.1016/J.Jsat.2007.01.008 |
0.49 |
|
| 2008 |
Brunette MF, O'Keefe C, Zimmet S, Wojcik J, Dawson R, Brownell E, Green AI. Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia Journal of Dual Diagnosis. 4: 344-354. DOI: 10.1080/15504260802313816 |
0.514 |
|
| 2007 |
Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. The Journal of Clinical Psychiatry. 68: 1163-71. PMID 17854239 DOI: 10.4088/Jcp.V68N0801 |
0.39 |
|
| 2007 |
Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotoxicity Research. 11: 33-40. PMID 17449446 DOI: 10.1007/Bf03033480 |
0.473 |
|
| 2007 |
Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. The American Journal of Psychiatry. 164: 402-8. PMID 17329463 DOI: 10.1176/Ajp.2007.164.3.402 |
0.474 |
|
| 2007 |
Altamura AC, Mundo E, Bassetti R, Green A, Lindenmayer JP, Alphs L, Meltzer HY. Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 89: 140-6. PMID 17097854 DOI: 10.1016/J.Schres.2006.08.023 |
0.361 |
|
| 2007 |
Green AI. Substance abuse and schizophrenia: Pharmacological approaches Journal of Dual Diagnosis. 3: 63-72. DOI: 10.1300/J374v03n02_08 |
0.303 |
|
| 2007 |
Green AI, Schatzberg AF. Joseph J Schildkraut, 1934–2006 Neuropsychopharmacology. 32: 1855-1856. DOI: 10.1038/Sj.Npp.1301474 |
0.391 |
|
| 2006 |
Green AI, Brown ES. Comorbid schizophrenia and substance abuse. The Journal of Clinical Psychiatry. 67: e08. PMID 17081075 DOI: 10.4088/Jcp.0906E08 |
0.471 |
|
| 2006 |
Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. The Journal of Clinical Psychiatry. 67: 31-5; quiz 36-7. PMID 16961422 |
0.382 |
|
| 2006 |
Drake RE, Green AI. Current research on co-occurring substance-use disorder in schizophrenia. Schizophrenia Bulletin. 32: 616-7. PMID 16896056 DOI: 10.1093/Schbul/Sbl020 |
0.45 |
|
| 2006 |
Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/J.Schres.2006.06.021 |
0.415 |
|
| 2006 |
Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin. 32: 637-43. PMID 16782758 DOI: 10.1093/Schbul/Sbl003 |
0.439 |
|
| 2006 |
Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/J.Schres.2005.10.016 |
0.354 |
|
| 2005 |
Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of Psychiatric Practice. 11: 315-39. PMID 16184072 DOI: 10.1097/00131746-200509000-00005 |
0.412 |
|
| 2005 |
Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. The Journal of Clinical Psychiatry. 66: 21-6. PMID 16107180 |
0.398 |
|
| 2005 |
Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Current Psychiatry Reports. 7: 283-91. PMID 16098282 DOI: 10.1007/S11920-005-0082-8 |
0.464 |
|
| 2005 |
Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, Lieberman JA, Glick I, Patel JK. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research. 78: 161-9. PMID 15950436 DOI: 10.1016/J.Schres.2005.04.017 |
0.38 |
|
| 2005 |
Niznikiewicz MA, Patel JK, McCarley R, Sutton J, Chau DT, Wojcik J, Green AI. Clozapine action on auditory P3 response in schizophrenia. Schizophrenia Research. 76: 119-21. PMID 15927806 DOI: 10.1016/J.Schres.2004.11.012 |
0.375 |
|
| 2005 |
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/Archpsyc.62.4.361 |
0.395 |
|
| 2005 |
Brunette MF, Noordsy DL, Buckley PF, Green AI. Pharmacologic treatments for co-occurring substance use disorders in patients with schizophrenia: A research review Journal of Dual Diagnosis. 1: 41-55. DOI: 10.1300/J374V01N02_04 |
0.458 |
|
| 2004 |
Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophrenia Bulletin. 30: 577-86. PMID 15631247 DOI: 10.1093/Oxfordjournals.Schbul.A007102 |
0.314 |
|
| 2004 |
Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research. 128: 9-20. PMID 15450910 DOI: 10.1016/J.Psychres.2004.05.005 |
0.633 |
|
| 2004 |
Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Current Psychiatry Reports. 6: 391-9. PMID 15355762 DOI: 10.1007/S11920-004-0026-8 |
0.358 |
|
| 2004 |
Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/Bjp.185.1.18 |
0.411 |
|
| 2004 |
Elman I, Rott D, Green AI, Langleben DD, Lukas SE, Goldstein DS, Breier A. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology. 176: 369-75. PMID 15179540 DOI: 10.1007/S00213-004-1890-Y |
0.358 |
|
| 2004 |
Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcoholism, Clinical and Experimental Research. 28: 302-12. PMID 15112938 DOI: 10.1097/01.Alc.0000113413.37910.D7 |
0.449 |
|
| 2004 |
Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 66: 125-35. PMID 15061244 DOI: 10.1016/J.Schres.2003.08.001 |
0.463 |
|
| 2003 |
Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Current Psychiatry Reports. 5: 340-6. PMID 13678553 DOI: 10.1007/S11920-003-0066-5 |
0.473 |
|
| 2003 |
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/Appi.Ajp.160.8.1396 |
0.401 |
|
| 2003 |
Stone WS, Seidman LJ, Wojcik JD, Green AI. Glucose effects on cognition in schizophrenia. Schizophrenia Research. 62: 93-103. PMID 12765749 DOI: 10.1016/S0920-9964(02)00406-1 |
0.335 |
|
| 2003 |
Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. The Psychiatric Clinics of North America. 26: 115-39. PMID 12683263 DOI: 10.1016/S0193-953X(02)00014-X |
0.438 |
|
| 2003 |
Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry. 60: 82-91. PMID 12511175 DOI: 10.1001/Archpsyc.60.1.82 |
0.331 |
|
| 2003 |
Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Research. 60: 81-5. PMID 12505141 DOI: 10.1016/S0920-9964(02)00231-1 |
0.502 |
|
| 2003 |
Kahn R, Lieberman J, Charles C, Sharma T, Zipursky R, Gur R, Tohen M, Green A, McEvoy J, Perkins D, Hamer R, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. P.2.131 Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia European Neuropsychopharmacology. 13: S337. DOI: 10.1016/S0924-977X(03)92084-0 |
0.415 |
|
| 2003 |
Sharma T, Lieberman J, McEvoy J, Perkins D, Hamer R, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. S.14.05 Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia European Neuropsychopharmacology. 13: S134-S135. DOI: 10.1016/S0924-977X(03)91655-5 |
0.355 |
|
| 2003 |
Lieberman J, Charles HC, Sharma T, Zipursky R, Kahn R, Gur R, Tohen M, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, et al. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia Schizophrenia Research. 60: 293. DOI: 10.1016/S0920-9964(03)80491-7 |
0.425 |
|
| 2003 |
McEvoy J, Lieberman J, Perkins D, Hamer R, Sharma T, Zipursky R, Kahn R, Gur R, Centorrino F, Glick I, Green A, Nemeroff C, Rothschild A, Strakowski S, Tohen M, et al. Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia Schizophrenia Research. 60: 313. DOI: 10.1016/S0920-9964(03)80257-8 |
0.357 |
|
| 2003 |
Green A, Keung W, Chau D, Dawson R, Mesholam R, Schildkraut J. Clozapine limits alcohol drinking in hamsters: Implications for treatment of schizophrenia Schizophrenia Research. 60: 312. DOI: 10.1016/S0920-9964(03)80252-9 |
0.659 |
|
| 2003 |
Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occuring substance use disorders Current Psychiatry Reports. 5: 340-346. |
0.334 |
|
| 2002 |
Green AI, Salomon MS, Brenner MJ, Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Current Drug Targets. Cns and Neurological Disorders. 1: 129-39. PMID 12769622 DOI: 10.2174/1568007024606230 |
0.524 |
|
| 2002 |
Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Research. 111: 11-20. PMID 12140115 DOI: 10.1016/S0165-1781(02)00123-3 |
0.589 |
|
| 2002 |
Elman I, Goldstein DS, Green AI, Eisenhofer G, Folio CJ, Holmes CS, Pickar D, Breier A. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 293-300. PMID 12093603 DOI: 10.1016/S0893-133X(02)00314-7 |
0.341 |
|
| 2001 |
Stone WS, Faraone SV, Seidman LJ, Green AI, Wojcik JD, Tsuang MT. Concurrent validation of schizotaxia: a pilot study. Biological Psychiatry. 50: 434-40. PMID 11566160 DOI: 10.1016/S0006-3223(01)01116-7 |
0.41 |
|
| 2001 |
Faraone SV, Green AI, Seidman LJ, Tsuang MT. "Schizotaxia": clinical implications and new directions for research. Schizophrenia Bulletin. 27: 1-18. PMID 11215539 DOI: 10.1093/Oxfordjournals.Schbul.A006849 |
0.405 |
|
| 2000 |
Green AI. What is the relationship between schizophrenia and substance abuse? The Harvard Mental Health Letter / From Harvard Medical School. 17: 8. PMID 11015759 |
0.308 |
|
| 2000 |
Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. General Hospital Psychiatry. 22: 224-35. PMID 10936629 DOI: 10.1016/S0163-8343(00)00081-5 |
0.375 |
|
| 2000 |
Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin. 26: 441-9. PMID 10885642 DOI: 10.1093/Oxfordjournals.Schbul.A033464 |
0.489 |
|
| 2000 |
Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. The American Journal of Psychiatry. 157: 982-6. PMID 10831480 DOI: 10.1176/Appi.Ajp.157.6.982 |
0.522 |
|
| 2000 |
Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. Journal of Clinical Psychopharmacology. 20: 94-8. PMID 10653215 DOI: 10.1097/00004714-200002000-00016 |
0.469 |
|
| 1999 |
Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review of Psychiatry. 6: 287-96. PMID 10370435 DOI: 10.3109/10673229909017206 |
0.654 |
|
| 1999 |
Strous RD, Patel JK, Zimmet S, Green AI. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. The American Journal of Psychiatry. 156: 973-4. PMID 10360153 DOI: 10.1176/Ajp.156.6.973A |
0.416 |
|
| 1999 |
Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biological Psychiatry. 45: 1412-8. PMID 10356622 DOI: 10.1016/S0006-3223(98)00364-3 |
0.412 |
|
| 1998 |
Berman I, Merson A, Viegner B, Losonczy MF, Pappas D, Green AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. The Journal of Nervous and Mental Disease. 186: 150-6. PMID 9521350 DOI: 10.1097/00005053-199803000-00003 |
0.37 |
|
| 1997 |
Patel JK, Green AI, Kalinowski A, Tsuang MT. Evaluation of a complex case: the value of a drug washout period. The American Journal of Psychiatry. 154: 1747-50. PMID 9396956 DOI: 10.1176/Ajp.154.12.1747 |
0.343 |
|
| 1997 |
Kando JC, Shepski JC, Satterlee W, Patel JK, Reams SG, Green AI. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. The Annals of Pharmacotherapy. 31: 1325-34. PMID 9391688 DOI: 10.1177/106002809703101110 |
0.41 |
|
| 1997 |
Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia Research. 25: 1-10. PMID 9176922 DOI: 10.1016/S0920-9964(96)00098-9 |
0.332 |
|
| 1997 |
Stone WS, Seidman LJ, Kalinowski A, Shagrin B, Patel JK, Shafa R, Canuso C, Schildkraut JJ, Green AI. Effects of clozapine on cognitive functions in treatment-refractory schizophrenia Schizophrenia Research. 24: 188-189. DOI: 10.1016/S0920-9964(97)82539-X |
0.594 |
|
| 1995 |
Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Review of Psychiatry. 3: 1-9. PMID 9384923 DOI: 10.3109/10673229509017159 |
0.63 |
|
| 1995 |
Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. Comprehensive Psychiatry. 36: 6-10. PMID 7705089 DOI: 10.1016/0010-440X(95)90092-A |
0.354 |
|
| 1995 |
Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. Journal of Clinical Psychopharmacology. 15: 206-10. PMID 7635998 DOI: 10.1097/00004714-199506000-00009 |
0.38 |
|
| 1994 |
Kahn M, Green AI. Psychosis, delirium, or both? Harvard Review of Psychiatry. 2: 34-8. PMID 9384877 DOI: 10.3109/10673229409017111 |
0.366 |
|
| 1993 |
Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research. 46: 139-49. PMID 8483973 DOI: 10.1016/0165-1781(93)90016-A |
0.621 |
|
| 1993 |
Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ. Haloperidol response and plasma catecholamines and their metabolites. Schizophrenia Research. 10: 33-7. PMID 8369230 DOI: 10.1016/0920-9964(93)90074-S |
0.59 |
|
| 1993 |
Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, Tsuang MT. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biological Psychiatry. 33: 575-84. PMID 8101100 DOI: 10.1016/0006-3223(93)90095-U |
0.359 |
|
| 1992 |
GREEN AI. International Perspectives in Schizophrenia: Biological, Social and Epidemiological Findings American Journal of Psychiatry. 149: 566-566. DOI: 10.1176/Ajp.149.4.566 |
0.36 |
|
| 1991 |
Reich JH, Green AI. Effect of personality disorders on outcome of treatment. The Journal of Nervous and Mental Disease. 179: 74-82. PMID 1990074 DOI: 10.1097/00005053-199102000-00003 |
0.304 |
|
| 1990 |
Green AI, Salzman C. Clozapine: benefits and risks. Hospital & Community Psychiatry. 41: 379-80. PMID 2158938 DOI: 10.1176/Ps.41.4.379 |
0.332 |
|
| 1970 |
Kuhar MJ, Green AI, Snyder SH, Gfeller E. Separation of synaptosomes storing catecholamines and gamma-aminobutyric acid in rat corpus striatum. Brain Research. 21: 405-17. PMID 5456733 DOI: 10.1016/0006-8993(70)90420-8 |
0.501 |
|
| 1970 |
Snyder SH, Kuhar MJ, Green AI, Coyle JT, Shaskan EG. Uptake and Subcellular Localization of Neurotransmitters in the Brain International Review of Neurobiology. 13: 127-158. DOI: 10.1016/S0074-7742(08)60168-3 |
0.532 |
|
| 1969 |
Gfeller E, Green A, Snyder SH. Regional differences in (3H)noradrenaline accumulation in monkey brain (Macaca irus). Brain Research. 11: 263-7. PMID 4972653 DOI: 10.1016/0006-8993(68)90089-9 |
0.367 |
|
| 1968 |
Snyder SH, Green AI, Hendley ED. Kinetics of H3-norepinephrine accumulation into slices from different regions of the rat brain. The Journal of Pharmacology and Experimental Therapeutics. 164: 90-102. PMID 5722109 |
0.565 |
|
| 1968 |
Snyder SH, Green A, Hendley ED, Gfeller E. Noradrenaline: kinetics of accumulation into slices from different regions of rat brain. Nature. 218: 174-6. PMID 4967055 DOI: 10.1038/218174A0 |
0.632 |
|
| Show low-probability matches. |